New York, Jan 24, 2026, 13:07 EST — Market closed.
- XLV dipped 0.51% Friday, underperforming the S&P 500, which ended flat.
- Lawmakers pressed major health insurers on rising premiums and industry consolidation, signaling ongoing policy risks.
- Look for UnitedHealth’s update on Jan. 27 and Regeneron’s report due Jan. 30 to dominate the week ahead.
The Health Care Select Sector SPDR Fund (XLV) dropped 0.51% to close at $157.48 on Friday. The S&P 500 Health Care index also slipped, down 0.56% by the closing bell.
This week matters because politics, payment rules, and earnings collide. The biggest players might act like defensives—until a reimbursement change or a Washington headline shifts the calculus.
Investors seem to be demanding proof over promises following a jittery January. While health care sectors have shown some resilience, they haven’t provided a clear safe haven.
The Dow dropped 0.58% on Friday. The S&P 500 barely moved, and the Nasdaq gained 0.28%, Reuters reported. Intel weighed on the market after issuing a weak outlook.
Washington is back in the health insurance spotlight. On Thursday, executives from CVS Health, Cigna, UnitedHealth, and Elevance testified before a House panel about soaring commercial insurance prices. “Market power is concentrated,” Representative Lori Trahan stated bluntly. UnitedHealth CEO Stephen Hemsley pushed back, saying insurance costs “reflect the cost of healthcare itself.” According to UnitedHealth’s written testimony, the company plans to issue rebates to most Affordable Care Act customers in 2026. Republicans dismissed the hearing as a political stunt. Reuters
The witness list featured Hemsley, CVS chief David Joyner, Elevance CEO Gail Boudreaux, Cigna CEO David Cordani, and Ascendion CEO Paul Markovich, according to the American Hospital Association.
The next major catalyst will be earnings. UnitedHealth plans to release its fourth-quarter and full-year results on Jan. 27, as listed in its investor calendar.
Regeneron will release its earnings on Jan. 30 before the U.S. market opens and hold a conference call at 8:30 a.m. Eastern, the company announced.
Reimbursement risk — how insurers and government programs cover care costs — is already hitting smaller medtech stocks. Truist Securities downgraded Inspire Medical Systems to hold and slashed its price target from $120 to $96, pointing to a Medicare billing-code change. Analyst Richard Newitter noted that “multiple expansion could be limited,” referring to the valuations investors pay for earnings. StreetInsider.com
Biotech shook things up as Corcept Therapeutics surged 45% following news that its Phase 3 ROSELLA trial hit the overall-survival goal in platinum-resistant ovarian cancer. Trial investigator Alexander B. Olawaiye called it “positioned to become a new standard-of-care.” The FDA’s target action date is set for July 11. Investing.com
Friday’s session ended with mixed results among big caps. Centene climbed 1.5%, but GE HealthCare dropped 2.6%.
The upcoming week holds clear risks: a harsher policy stance from Washington, an unexpected hit on reimbursements, or a spike in medical costs during earnings could quickly turn “defensive” into “dead money.” For smaller players, a tweak in billing codes or a regulator’s scrutiny might wipe out months of gains in a flash.
Traders are eyeing Tuesday for UnitedHealth’s update and Friday for Regeneron’s report. The managed-care group remains under pressure from last week’s hearing, with potential fallout still in play.
